相关实验视频

Updated: Jun 30, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

新辅助剂PD-1 Plus化疗用于局部发达的食道状细胞癌

Ting Qian¹, Delin Liu¹, Guochun Cao¹

¹Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.

Technology in cancer research & treatment

|March 18, 2024

概括

使用托利帕利马布,帕克利塔塞尔和西斯普拉丁的新辅助免疫化疗对局部晚期食道癌很有前途,实现了高反应率和生存益处. 这种组合疗法需要进一步研究,作为一种潜在的治疗选择.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
胃肠道癌症研究研究

背景情况:

编程细胞死亡-1 (PD-1) 抑制剂激活T细胞并抑制瘤生长.
治疗食道癌的新辅助化疗是积极的临床研究领域.
将PD-1抑制剂与化疗相结合可能会提高治疗效率.

研究的目的:

探索新辅助剂托利帕利马布,帕克利塔塞尔和西斯普拉丁对局部晚期食道状细胞癌的疗效.
评估治疗反应,病理阶段和生存结果.

主要方法:

患者接受了两次手术前的toripalimab,paclitaxel和cisplatin治疗周期.
通过病理完整反应 (pCR),主要病理反应和客观反应率来评估有效性.
分析了手术切除 (R0) 和生存数据 (无进展生存,总生存).

主要成果:

观察到高比例的pCR (29.0%),主要病理反应 (41.9%) 和客观反应 (80.6%).
实现了统计学上显著的下降阶段 (P < .05).
一年无进展生存率为87.1%,一年生存率为96.8%,两年生存率为83.9%.

结论:

托利帕利马布,帕克利塔塞尔和西斯普拉丁的组合显示出作为局部晚期食道癌的新辅助疗法的潜力.
该疗法显示了可管理的不良影响和有希望的生存结果.
需要对这种免疫化学疗法方案进行进一步的研究.

关键词:

总的来说是生存.食管状细胞癌的癌症新辅助免疫化学疗法新辅助免疫化学疗法病理学的完整反应.编程死亡 1 编程死亡 1 没有进展的生存率.胸部外科手术胸部外科手术

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

相关概念视频

Barrett Esophagus-II: Clinical Manifestations and Management

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Barrett Esophagus-I: Introduction

Barrett Esophagus-I: Introduction

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...